世界の組み換えタンパク質市場(~2026年):製品別(成長因子、ケモカイン、構造タンパク質、膜タンパク質)、用途別(創薬・開発、学術研究)、エンドユーザー別(バイオテクノロジー企業、CRO)

◆英語タイトル:Recombinant Proteins Market by Product (Growth Factors, Chemokines, Structural Proteins, Membrane Proteins), Application (Drug Discovery & Development, Academic Research), End User (Biotechnology Companies, CROs) - Global Forecast to 2026
◆商品コード:BT7839
◆発行会社(リサーチ会社):MarketsandMarkets
◆発行日:2021年2月16日
◆ページ数:172
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single User(1名様閲覧)USD4,950 ⇒換算¥564,300見積依頼/購入/質問フォーム
Multi User (Five User)USD6,650 ⇒換算¥758,100見積依頼/購入/質問フォーム
Corporate License (全社内共有可)USD8,150 ⇒換算¥929,100見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はMarketsandMarkets社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
MarketsandMarkets社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

マーケッツアンドマーケッツ社は、世界の組み換えタンパク質市場規模が2021年10億ドルから2026年17億ドルまで、年平均9.8%成長すると予測しています。本調査レポートでは、組み換えタンパク質の世界市場について調査・分析し、イントロダクション、調査手法、エグゼクティブサマリー、プレミアムインサイト、市場概要、製品別(成長因子、ケモカイン、構造タンパク質、膜タンパク質)分析、用途別(創薬・開発、学術研究)分析、エンドユーザー別(製薬・バイオ医薬品会社、バイオテクノロジー企業、学術研究機関、CRO)分析、地域別分析、競争状況、企業情報などを掲載しています。
・イントロダクション
・調査手法
・エグゼクティブサマリー
・プレミアムインサイト
・市場概要
・組み換えタンパク質の世界市場規模:製品別(成長因子、ケモカイン、構造タンパク質、膜タンパク質)
・組み換えタンパク質の世界市場規模:用途別(創薬・開発、学術研究)
・組み換えタンパク質の世界市場規模:エンドユーザー別(製薬・バイオ医薬品会社、バイオテクノロジー企業、学術研究機関、CRO)
・組み換えタンパク質の世界市場規模:地域別
・競争状況
・企業情報
【レポートの概要】

“The global recombinant proteins market is projected to reach USD 1.7billion by 2026 from USD 1.0billion in 2021, at a CAGR of 9.8% during the forecast period.”
The market growth is primarily driven by factors such as increasing government investments and R&D expenditure in pharmaceutical & biotechnology companies, growing industryacademia collaborations, and the patent expiry of biologic products. Emerging markets in Asian countries and the rising focus on personalized medicine & protein therapeutics are other factors expected to offer strong growth opportunities for players in the recombinant proteins market. In contrast, the declining cost of recombinant proteins may restrict market growth to a certain extent

“The pharmaceutical & biopharmaceutical companiessegmentis expected to dominate the market during the forecast period.”
Based on end users, the recombinant proteins market is segmented into pharmaceutical & biopharmaceutical companies, biotechnology companies, academic research institutes, contract research organizations, and other end users. Pharmaceutical & biopharmaceutical companies accounted for the largest share of the end-user market in 2020. The large share of this segment is attributed to the high requirement of recombinant proteins for prognostic, predictive, or diagnostic identification and the quantification of biomarkers in drug discovery & development. Moreover, factors such as the patent expiration of blockbuster drugs and increasing investments in drug development support the growth of this segment.

“Biologics segment will witness the highest growth intherecombinant proteins market.”
Based on type, the drug discovery & development market is segmented into biologics, vaccines, and cell & gene therapy. Biologics accounted for the largest share of the drug discovery & development application for the recombinant proteins market and is expected to register the highest CAGR during the forecast period. The large share of the biologics segment is attributed to the factors such as the increasing prevalence & incidence of target diseases, increasing research & development, and the strong development pipeline for recombinant protein-based biologics.

“North America will dominate the market during the forecast period.”
Geographically, the recombinant proteins market is segmented into North America, Europe, the Asia Pacific, and the Rest of the World. In 2019, North America accounted for the largest share of therecombinant proteins market.The large share of this region in the global market is attributed to the rising incidences of chronic & infectious diseases, increasing R&D spending, increasing research activities, favorable government funding, and the presence of key players in this region.

The primary interviews conducted for this report can be categorized as follows:
• By Company Type -Tier 1: 36%, Tier 2: 45%,and Tier 3: 19%
• By Designation – C-level:33%, D-level:40%, and Others:27%
• By Region – North America:36%, Europe:28%, Asia Pacific:19%, and Rest of the World: 17%

List of Companies Profiled in the Report
• Thermo Fisher Scientific, Inc. (US)
• Miltenyi Biotech (Germany)
• Sino Biological Inc. (China)
• Merck KGaA (Germany)
• Abcam plc (UK)
• Biolegend (US)
• Bio-Rad Laboratories, Inc. (US)
• GenScript Biotech Corporation (China)
• Enzo Life Sciences, Inc. (US)
• BPS Bioscience, Inc. (US)
• PeproTech, Inc. (US)
• Proteintech Group, Inc. (US)
• Abnova Corporation (Taiwan)
• R&D Systems (US)
• STEMCELL Technologies Inc (Canada)
• RayBiotech Inc (US)
• CellGenix GmbH (Germany)
• ACROBiosystems (US)
• ProSpec-TechnoGene Ltd. (Israel)
• Neuromics (US)
• RICHCORE LIFESCIENCES PVTLTD (India)
• Icosagen AS (US)
• ProteoGenix (France)
• United States Biological (US)
• StressMarq BiosciencesInc (Canada)
• Aviva Systems Biology Corporation (US)

Research Coverage:
This report provides a detailed picture of the global recombinant proteinsmarket. It aims at estimating the size and future growth potential of the market across different segments, such as product,application, end userand region. The report also analyzes factors (such as drivers, restraints,and opportunities) affecting market growth. It evaluates the opportunities in the market for stakeholders and provides details of the competitive landscape for market leaders. The report also studies micromarkets with respect to their growth trends, prospects, and contributions to the total recombinant proteins market. The report forecasts the revenue of the market segments with respect to four major regions.

Reasons to Buy the Report:
The report provides insights on the following pointers:
• Market Penetration: Comprehensive information on recombinant proteins offered by the top 25 players in the recombinant proteins market. The report analyses the recombinant proteins market by product, application, end userand region.
• Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various recombinant proteins across key geographic regions.
• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the recombinant proteins market.
• Competitive Assessment: In-depth assessment of market ranking and strategies of the leading players in the recombinant proteins market.

【レポートの目次】

1 INTRODUCTION 22
1.1 OBJECTIVES OF THE STUDY 22
1.2 MARKET DEFINITION 22
1.2.1 INCLUSION & EXCLUSIONS 23
1.3 MARKET SCOPE 24
FIGURE 1 RECOMBINANT PROTEINS MARKET 24
1.3.1 YEARS CONSIDERED FOR THE STUDY 24
1.4 CURRENCY 25
1.5 LIMITATIONS 25
1.6 STAKEHOLDERS 25
2 RESEARCH METHODOLOGY 26
2.1 RESEARCH DATA 26
FIGURE 2 RESEARCH DESIGN 26
2.2 SECONDARY DATA 27
2.2.1 SECONDARY SOURCES 27
2.3 PRIMARY DATA 28
2.3.1 KEY DATA FROM PRIMARY SOURCES 28
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 29
2.4 MARKET SIZE ESTIMATION 29
2.4.1 BOTTOM-UP APPROACH 29
FIGURE 4 MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH 30
2.4.2 TOP-DOWN APPROACH 30
FIGURE 5 MARKET SIZE ESTIMATION: TOP-DOWN APPROACH 30
2.4.3 GROWTH FORECAST 30
2.5 MARKET BREAKDOWN AND DATA TRIANGULATION 30
FIGURE 6 DATA TRIANGULATION METHODOLOGY 31
2.6 ASSUMPTIONS FOR THE STUDY 32
3 EXECUTIVE SUMMARY 33
FIGURE 7 RECOMBINANT PROTEINS MARKET, BY PRODUCT,
2021 VS. 2026 (USD MILLION) 33
FIGURE 8 RECOMBINANT PROTEINS MARKET, BY APPLICATION,
2021 VS. 2026 (USD MILLION) 34
FIGURE 9 RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY & DEVELOPMENT APPLICATION, BY TYPE, 2021–2026 (USD MILLION) 35
FIGURE 10 RECOMBINANT PROTEINS MARKET, BY END USER,
2021 VS. 2026 (USD MILLION) 36
FIGURE 11 GEOGRAPHIC SNAPSHOT OF THE GLOBAL RECOMBINANT PROTEINS MARKET 37
4 PREMIUM INSIGHTS 39
4.1 RECOMBINANT PROTEINS MARKET OVERVIEW 39
FIGURE 12 INCREASING GOVERNMENT INVESTMENTS & THE RISING FOCUS ON PERSONALIZED MEDICINE TO DRIVE MARKET GROWTH DURING THE FORECAST PERIOD 39
4.2 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET, BY APPLICATION & BY COUNTRY (2021) 40
FIGURE 13 THE DRUG DISCOVERY & DEVELOPMENT SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE, BY APPLICATION, FOR 2021 40
4.3 RECOMBINANT PROTEINS MARKET, BY END USER, 2021-2026 41
FIGURE 14 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES ARE EXPECTED TO BE THE LARGEST END USERS OF RECOMBINANT PROTEINS DURING THE FORECAST PERIOD 41
4.4 RECOMBINANT PROTEINS MARKET: GEOGRAPHIC SNAPSHOT 42
FIGURE 15 CHINA TO REGISTER THE HIGHEST GROWTH DURING THE FORECAST PERIOD 42
5 MARKET OVERVIEW 43
5.1 INTRODUCTION 43
5.2 MARKET DYNAMICS 43
FIGURE 16 RECOMBINANT PROTEINS MARKET: DRIVERS, RESTRAINTS, AND OPPORTUNITIES 43
5.2.1 DRIVERS 44
5.2.1.1 Rising government funding and increasing R&D expenditure in pharmaceutical & biotechnology companies 44
TABLE 1 GOVERNMENT FUNDING FOR LIFE SCIENCE RESEARCH (2017-2020) 44
5.2.1.2 The high prevalence of infectious & chronic diseases 45
5.2.1.3 Growing industry-academia collaborations 45
5.2.1.4 Patent expiry of biologics 46
5.2.2 RESTRAINTS 46
5.2.2.1 The declining cost of recombinant proteins 46
5.2.3 OPPORTUNITIES 46
5.2.3.1 Emerging economies 46
5.2.3.2 Rising focus on personalized medicine and protein therapeutics 47
TABLE 2 COMMERCIALIZED RECOMBINANT PROTEINS USED IN MEDICINE 48
5.2.3.3 Increasing focus on biomarker discovery 48
5.2.4 COVID IMPACT ANALYSIS 48
5.3 PRICING ANALYSIS 50
TABLE 3 PRICE OF RECOMBINANT PROTEINS (USD) 50
5.4 STAKEHOLDER ANALYSIS 50
FIGURE 17 RECOMBINANT PROTEINS MARKET- STAKEHOLDER ANALYSIS 51
5.5 VALUE CHAIN ANALYSIS 52
FIGURE 18 VALUE CHAIN ANALYSIS: MAJOR VALUE IS ADDED DURING THE MANUFACTURING AND ASSEMBLY PHASE 52
5.6 RECOMBINANT PROTEINS FORMS AN INTEGRAL PART OF BIOTECHNOLOGY 53
FIGURE 19 BIOTECHNOLOGY ECOSYSTEM ANALYSIS 53
5.7 PORTER’S FIVE FORCES ANALYSIS 54
FIGURE 20 REQUIREMENT OF HIGH CAPITAL INVESTMENTS TO RESTRICT THE ENTRY OF NEW PLAYERS 54
5.7.1 THREAT OF NEW ENTRANTS 54
5.7.2 THREAT OF SUBSTITUTES 55
5.7.3 BARGAINING POWER OF BUYERS 55
5.7.4 BARGAINING POWER OF SUPPLIERS 55
5.7.5 INTENSITY OF RIVALRY 55
6 RECOMBINANT PROTEINS MARKET, BY PRODUCT 56
6.1 INTRODUCTION 57
TABLE 4 RECOMBINANT PROTEINS MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 57
6.2 GROWTH FACTORS AND CHEMOKINES 57
6.2.1 THIS SEGMENT ACCOUNTED FOR THE LARGEST SHARE OF THE RECOMBINANT PROTEINS MARKET IN 2020 57
TABLE 5 GROWTH FACTORS AND CHEMOKINES MARKET, BY REGION,
2019–2026 (USD MILLION) 59
6.3 IMMUNE RESPONSE PROTEINS 59
6.3.1 IMMUNE CHECKPOINT PROTEINS PLAY A MAJOR ROLE IN CANCER IMMUNOTHERAPY 59
TABLE 6 IMMUNE RESPONSE PROTEINS MARKET, BY REGION,
2019–2026 (USD MILLION) 60
6.4 STRUCTURAL PROTEINS 60
6.4.1 STRUCTURAL PROTEINS ARE UTILIZED IN CELL CULTURE APPLICATIONS AS ATTACHMENT FACTORS 60
TABLE 7 STRUCTURAL PROTEINS MARKET, BY REGION, 2019–2026 (USD MILLION) 61
6.5 MEMBRANE PROTEINS 61
6.5.1 MEMBRANE PROTEINS ARE RESPONSIBLE FOR REGULATING PROCESSES THAT HELP BIOLOGICAL CELLS SURVIVE 61
TABLE 8 MEMBRANE PROTEINS MARKET, BY REGION, 2019–2026 (USD MILLION) 62
6.6 KINASE PROTEINS 62
6.6.1 KINASE PROTEINS PLAY A MAJOR ROLE IN SIGNAL TRANSDUCTION PATHWAYS 62
TABLE 9 KINASE PROTEINS MARKET, BY REGION, 2019–2026 (USD MILLION) 62
6.7 REGULATORY PROTEINS 63
6.7.1 REGULATORY PROTEINS HELP UNDERSTAND CELL CYCLE REGULATION AND CARCINOGENESIS 63
TABLE 10 REGULATORY PROTEINS MARKET, BY REGION, 2019–2026 (USD MILLION) 63
6.8 RECOMBINANT METABOLIC ENZYMES 63
6.8.1 ENZYMES REGULATE PROTEIN INTERACTIONS 63
TABLE 11 RECOMBINANT METABOLIC ENZYMES MARKET, BY REGION,
2019–2026 (USD MILLION) 63
6.9 ADHESION MOLECULES AND RECEPTORS 64
6.9.1 CELL ADHESION MOLECULES FACILITATE EXTRACELLULAR MATRIX (ECM) INTERACTIONS 64
TABLE 12 ADHESION MOLECULES AND RECEPTORS MARKET, BY REGION,
2019–2026 (USD MILLION) 64
6.10 OTHER RECOMBINANT PROTEINS 64
TABLE 13 OTHER RECOMBINANT PROTEINS MARKET, BY REGION,
2019–2026 (USD MILLION) 64
7 RECOMBINANT PROTEINS MARKET, BY APPLICATION 65
7.1 INTRODUCTION 66
TABLE 14 RECOMBINANT PROTEINS MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 66
7.2 DRUG DISCOVERY & DEVELOPMENT 66
TABLE 15 RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2019-2026 (USD MILLION) 67
TABLE 16 RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2019-2026 (USD MILLION) 67
7.2.1 BIOLOGICS 67
7.2.1.1 Biologics are used to treat cancer, autoimmune diseases, and other serious disorders 67
TABLE 17 RECOMBINANT PROTEIN BIOLOGICS DRUGS 68
TABLE 18 RECOMBINANT PROTEINS MARKET FOR BIOLOGICS, BY REGION,
2019-2026 (USD MILLION) 68
7.2.2 VACCINES 68
7.2.2.1 Rising incidences of infectious diseases to boost the market growth for vaccines 68
TABLE 19 RECOMBINANT PROTEINS MARKET FOR VACCINES, BY REGION,
2019-2026 (USD MILLION) 69
7.2.3 CELL & GENE THERAPY 69
7.2.3.1 Stem cell therapy and CART therapies have increased the demand for recombinant proteins 69
TABLE 20 RECOMBINANT PROTEINS MARKET FOR CELL & GENE THERAPY, BY REGION, 2019-2026 (USD MILLION) 70
7.3 ACADEMIC RESEARCH STUDIES 70
7.3.1 RECOMBINANT PROTEINS ARE USED IN MOLECULAR AND GENE EXPRESSION STUDIES, THUS AIDING MARKET GROWTH 70
TABLE 21 RECOMBINANT PROTEINS MARKET FOR ACADEMIC RESEARCH STUDIES,
BY REGION, 2019-2026 (USD MILLION) 71
7.4 BIOPHARMACEUTICAL PRODUCTION 71
7.4.1 RECOMBINANT PROTEINS ARE WIDELY USED FOR THE DEVELOPMENT OF PROTEIN-BASED DRUGS 71
TABLE 22 RECOMBINANT PROTEINS MARKET FOR BIOPHARMACEUTICAL PRODUCTION, BY REGION, 2019-2026 (USD MILLION) 71
7.5 BIOTECHNOLOGY RESEARCH 72
7.5.1 THE INCREASING NUMBER OF RESEARCH PROJECTS IN GENOMICS TO DRIVE MARKET GROWTH 72
TABLE 23 RECOMBINANT PROTEINS MARKET FOR BIOTECHNOLOGY RESEARCH,
BY REGION, 2019-2026 (USD MILLION) 72
7.6 OTHER APPLICATIONS 73
TABLE 24 RECOMBINANT PROTEINS MARKET FOR OTHER APPLICATIONS, BY REGION, 2019-2026 (USD MILLION) 73
8 RECOMBINANT PROTEINS MARKET, BY END USER 74
8.1 INTRODUCTION 75
TABLE 25 RECOMBINANT PROTEINS MARKET, BY END USER,
2019–2026 (USD MILLION) 75
8.2 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES 75
8.2.1 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES ARE THE LARGEST END-USER SEGMENT FOR RECOMBINANT PROTEINS USED IN TARGET DETECTION & DRUG DISCOVERY 75
TABLE 26 RECOMBINANT PROTEINS MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY REGION, 2019–2026 (USD MILLION) 76
8.3 BIOTECHNOLOGY COMPANIES 76
8.3.1 INCREASING NUMBER OF PROJECTS FOR PROTEIN-BASED RESEARCH DRIVES MARKET GROWTH 76
TABLE 27 RECOMBINANT PROTEINS MARKET FOR BIOTECHNOLOGY COMPANIES,
BY REGION, 2019–2026 (USD MILLION) 77
8.4 ACADEMIC RESEARCH INSTITUTES 77
8.4.1 GROWING GOVERNMENT INVESTMENTS TO PROPEL MARKET GROWTH 77
TABLE 28 RECOMBINANT PROTEINS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY REGION, 2019–2026 (USD MILLION) 78
8.5 CONTRACT RESEARCH ORGANIZATIONS (CROS) 78
8.5.1 INCREASING OUTSOURCING OF SERVICES TO CROS DRIVES MARKET GROWTH 78
TABLE 29 RECOMBINANT PROTEINS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2019–2026 (USD MILLION) 79
8.6 OTHER END USERS 79
TABLE 30 RECOMBINANT PROTEINS MARKET FOR OTHER END USERS, BY REGION, 2019–2026 (USD MILLION) 79
9 RECOMBINANT PROTEIN MARKET, BY REGION 80
9.1 INTRODUCTION 81
TABLE 31 RECOMBINANT PROTEINS MARKET, BY REGION, 2019–2026 (USD MILLION) 81
9.2 NORTH AMERICA 81
FIGURE 21 NORTH AMERICA: RECOMBINANT PROTEINS MARKET SNAPSHOT 82
TABLE 32 NORTH AMERICA: RECOMBINANT PROTEINS MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 83
TABLE 33 NORTH AMERICA: RECOMBINANT PROTEINS MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 83
TABLE 34 NORTH AMERICA: RECOMBINANT PROTEINS MARKET, BY APPLICATION, 2019–2026 (USD MILLION) 84
TABLE 35 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY & DEVELOPMENT APPLICATION, BY TYPE, 2019–2026 (USD MILLION) 84
TABLE 36 NORTH AMERICA: RECOMBINANT PROTEINS MARKET, BY END USER,
2019–2026 (USD MILLION) 84
9.2.1 US 85
9.2.1.1 The US accounted for the largest share of the North American market for recombinant proteins during the forecast period 85
TABLE 37 US NIH BUDGET FOR VARIOUS DISCIPLINES, FY 2019 VS. FY 2020
(USD BILLION) 85
TABLE 38 US: RECOMBINANT PROTEINS MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 86
TABLE 39 US: RECOMBINANT PROTEINS MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 86
TABLE 40 US: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY & DEVELOPMENT APPLICATION, BY TYPE, 2019–2026 (USD MILLION) 87
TABLE 41 US: RECOMBINANT PROTEINS MARKET, BY END USER,
2019–2026 (USD MILLION) 87
9.2.2 CANADA 87
9.2.2.1 The high prevalence of cancer and favorable funding scenario in Canada is expected to support market growth 87
TABLE 42 CANADA: RECOMBINANT PROTEINS MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 88
TABLE 43 CANADA: RECOMBINANT PROTEINS MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 89
TABLE 44 CANADA: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY & DEVELOPMENT APPLICATION, BY TYPE, 2019–2026 (USD MILLION) 89
TABLE 45 CANADA: RECOMBINANT PROTEINS MARKET, BY END USER,
2019–2026 (USD MILLION) 89
9.3 EUROPE 90
TABLE 46 EUROPE: RECOMBINANT PROTEINS MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 90
TABLE 47 EUROPE: RECOMBINANT PROTEINS MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 91
TABLE 48 EUROPE: RECOMBINANT PROTEINS MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 91
TABLE 49 EUROPE: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY & DEVELOPMENT APPLICATION, BY TYPE, 2019–2026 (USD MILLION) 92
TABLE 50 EUROPE: RECOMBINANT PROTEINS MARKET, BY END USER,
2019–2026 (USD MILLION) 92
9.3.1 GERMANY 92
9.3.1.1 Germany held the largest share of the market in Europe in 2020 92
TABLE 51 GERMANY: RECOMBINANT PROTEINS MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 93
TABLE 52 GERMANY: RECOMBINANT PROTEINS MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 93
TABLE 53 GERMANY: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY & DEVELOPMENT APPLICATION, BY TYPE, 2019–2026 (USD MILLION) 94
TABLE 54 GERMANY: RECOMBINANT PROTEINS MARKET, BY END USER,
2019–2026 (USD MILLION) 94
9.3.2 UK 94
9.3.2.1 Government initiatives to drive market growth in the UK 94
TABLE 55 UK: RECOMBINANT PROTEINS MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 95
TABLE 56 UK: RECOMBINANT PROTEINS MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 95
TABLE 57 UK: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY &DEVELOPMENT APPLICATION, BY TYPE, 2019–2026 (USD MILLION) 96
TABLE 58 UK: RECOMBINANT PROTEINS MARKET, BY END USER,
2019–2026 (USD MILLION) 96
9.3.3 FRANCE 96
9.3.3.1 Infrastructural development and rising life science R&D supports market growth in France 96
TABLE 59 FRANCE: RECOMBINANT PROTEINS MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 97
TABLE 60 FRANCE: RECOMBINANT PROTEINS MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 97
TABLE 61 FRANCE: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY & DEVELOPMENT APPLICATION, BY TYPE, 2019–2026 (USD MILLION) 98
TABLE 62 FRANCE: RECOMBINANT PROTEINS MARKET, BY END USER,
2019–2026 (USD MILLION) 98
9.3.4 ITALY 98
9.3.4.1 Life science research investments and a favorable funding scenario are the key growth drivers for market growth 98
TABLE 63 ITALY: RECOMBINANT PROTEINS MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 99
TABLE 64 ITALY: RECOMBINANT PROTEINS MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 99
TABLE 65 ITALY: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY & DEVELOPMENT APPLICATION, BY TYPE, 2019–2026 (USD MILLION) 100
TABLE 66 ITALY: RECOMBINANT PROTEINS MARKET, BY END USER,
2019–2026 (USD MILLION) 100
9.3.5 SPAIN 100
9.3.5.1 A favorable scenario for research initiatives drives the market growth in Spain 100
TABLE 67 SPAIN: RECOMBINANT PROTEINS MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 101
TABLE 68 SPAIN: RECOMBINANT PROTEINS MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 101
TABLE 69 SPAIN: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY & DEVELOPMENT APPLICATION, BY TYPE, 2019–2026 (USD MILLION) 102
TABLE 70 SPAIN: RECOMBINANT PROTEINS MARKET, BY END USER,
2019–2026 (USD MILLION) 102
9.3.6 REST OF EUROPE (ROE) 102
TABLE 71 ROE: RECOMBINANT PROTEINS MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 103
TABLE 72 ROE: RECOMBINANT PROTEINS MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 103
TABLE 73 ROE: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY & DEVELOPMENT APPLICATION, BY TYPE, 2019–2026 (USD MILLION) 104
TABLE 74 ROE: RECOMBINANT PROTEINS MARKET, BY END USER,
2019–2026 (USD MILLION) 104
9.4 ASIA PACIFIC 104
FIGURE 22 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET SNAPSHOT 105
TABLE 75 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 106
TABLE 76 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 106
TABLE 77 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 107
TABLE 78 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY & DEVELOPMENT APPLICATION, BY TYPE, 2019–2026 (USD MILLION) 107
TABLE 79 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET, BY END USER,
2019–2026 (USD MILLION) 107
9.4.1 JAPAN 108
9.4.1.1 Advanced healthcare infrastructure to support market growth in Japan 108
TABLE 80 JAPAN: RECOMBINANT PROTEINS MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 108
TABLE 81 JAPAN: RECOMBINANT PROTEINS MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 109
TABLE 82 JAPAN: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY & DEVELOPMENT APPLICATION, BY TYPE, 2019–2026 (USD MILLION) 109
TABLE 83 JAPAN: RECOMBINANT PROTEINS MARKET, BY END USER,
2019–2026 (USD MILLION) 109
9.4.2 CHINA 110
9.4.2.1 China is the fastest-growing segment of the overall APAC market during the forecast period 110
TABLE 84 CHINA: RECOMBINANT PROTEINS MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 110
TABLE 85 CHINA: RECOMBINANT PROTEINS MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 111
TABLE 86 CHINA: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY & DEVELOPMENT APPLICATION, BY TYPE, 2019–2026 (USD MILLION) 111
TABLE 87 CHINA: RECOMBINANT PROTEINS MARKET, BY END USER,
2019–2026 (USD MILLION) 111
9.4.3 INDIA 112
9.4.3.1 Strong biopharmaceutical growth and the rising demand for pharmaceuticals are key market drivers for growth in India 112
TABLE 88 INDIA: RECOMBINANT PROTEINS MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 112
TABLE 89 INDIA: RECOMBINANT PROTEINS MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 113
TABLE 90 INDIA: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY & DEVELOPMENT APPLICATION, BY TYPE, 2019–2026 (USD MILLION) 113
TABLE 91 INDIA: RECOMBINANT PROTEINS MARKET, BY END USER,
2019–2026 (USD MILLION) 113
9.4.4 REST OF ASIA PACIFIC (ROAPAC) 114
TABLE 92 ROAPAC: RECOMBINANT PROTEINS MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 115
TABLE 93 ROAPAC: RECOMBINANT PROTEINS MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 115
TABLE 94 ROAPAC: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY & DEVELOPMENT APPLICATION, BY TYPE, 2019–2026 (USD MILLION) 116
TABLE 95 ROAPAC: RECOMBINANT PROTEINS MARKET, BY END USER,
2019–2026 (USD MILLION) 116
9.5 REST OF THE WORLD (ROW) 116
TABLE 96 ROW: RECOMBINANT PROTEINS MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 117
TABLE 97 ROW: RECOMBINANT PROTEINS MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 118
TABLE 98 ROW: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY & DEVELOPMENT APPLICATION, BY TYPE, 2019–2026 (USD MILLION) 118
TABLE 99 ROW: RECOMBINANT PROTEINS MARKET, BY END USER,
2019–2026 (USD MILLION) 118
10 COMPETITIVE LANDSCAPE 119
10.1 OVERVIEW 119
FIGURE 23 KEY PLAYERS ADOPTED ORGANIC AND INORGANIC GROWTH STRATEGIES BETWEEN 2018 AND 2020 119
FIGURE 24 MARKET EVOLUTION FRAMEWORK 120
10.2 MARKET SHARE ANALYSIS, 2019 121
FIGURE 25 RECOMBINANT PROTEINS MARKET, BY KEY PLAYERS, 2019 121
10.3 COMPETITIVE SCENARIO 122
10.3.1 PARTNERSHIPS, AGREEMENTS, AND COLLABORATIONS (2018–2020) 122
10.3.2 PRODUCT LAUNCHES & APPROVALS (2018-2020) 123
10.3.3 EXPANSIONS (2018-2020) 123
10.3.4 ACQUISITIONS (2018-2020) 124
10.4 COMPANY EVALUATION QUADRANT (2020) 124
10.4.1 VENDOR INCLUSION CRITERIA 124
10.4.2 STARS 124
10.4.3 EMERGING LEADERS 125
10.4.4 PERVASIVE PLAYERS 125
10.4.5 PARTICIPANTS 125
FIGURE 26 MNM VENDOR DIVE COMPARISON MATRIX: RECOMBINANT PROTEINS MARKET 125
11 COMPANY PROFILES 126
(Business Overview, Products Offered, Recent Developments, MnM View)*
11.1 R&D SYSTEMS 126
FIGURE 27 BIO‑TECHNE CORPORATION: COMPANY SNAPSHOT (2019) 126
11.2 THERMO FISHER SCIENTIFIC INC. 129
FIGURE 28 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2019) 129
11.3 MERCK KGAA 132
FIGURE 29 MERCK KGAA: COMPANY SNAPSHOT (2019) 132
TABLE 100 EXCHANGE RATES (USED FOR THE CONVERSION OF EURO TO USD) 133
11.4 ABCAM PLC 135
FIGURE 30 ABCAM PLC: COMPANY SNAPSHOT (2020) 135
11.5 ABNOVA CORPORATION 138
11.6 BIOLEGEND 139
11.7 BIO-RAD LABORATORIES, INC. 140
FIGURE 31 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2019) 141
11.8 BPS BIOSCIENCE, INC. 142
11.9 ENZO LIFE SCIENCES, INC. 144
FIGURE 32 ENZO BIOCHEM, INC.: COMPANY SNAPSHOT (2019) 144
11.10 GENSCRIPT BIOTECH CORPORATION 147
FIGURE 33 GENSCRIPT BIOTECH CORPORATION: COMPANY SNAPSHOT (2019) 147
11.11 MILTENYI BIOTEC 149
11.12 PEPROTECH, INC. 150
11.13 PROTEINTECH GROUP 151
11.14 SINO BIOLOGICAL INC. 154
11.15 ACROBIOSYSTEMS 156
11.16 AVIVA SYSTEMS BIOLOGY CORPORATION 157
11.17 CELLGENIX GMBH 158
11.18 ICOSAGEN AS 158
11.19 NEUROMICS 159
11.20 PROSPEC-TECHNOGENE LTD. 160
11.21 PROTEOGENIX 161
11.22 RAYBIOTECH, INC. 162
11.23 RICHCORE LIFESCIENCES PVT LTD 163
11.24 STEMCELL TECHNOLOGIES INC. 164
11.25 STRESSMARQ BIOSCIENCES INC. 165
11.26 UNITED STATES BIOLOGICAL 166
*Business Overview, Products Offered, Recent Developments, MnM View might not be captured in case of unlisted companies.
12 APPENDIX 167
12.1 DISCUSSION GUIDE 168
12.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 172
12.3 AVAILABLE CUSTOMIZATION 174
12.4 RELATED REPORT 174
12.5 AUTHOR DETAILS 175



【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[世界の組み換えタンパク質市場(~2026年):製品別(成長因子、ケモカイン、構造タンパク質、膜タンパク質)、用途別(創薬・開発、学術研究)、エンドユーザー別(バイオテクノロジー企業、CRO)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆